Quantcast
Last updated on April 24, 2014 at 11:09 EDT

Latest Cambridge Antibody Technology Stories

2014-04-10 08:29:30

MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a milestone payment from Merck, through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb® antibody...

2014-03-21 23:00:27

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Adalimumab Market, 2010-2018” to its store. Dallas, TX (PRWEB) March 22, 2014 Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and...

2014-03-16 16:20:46

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse(TM) (http://dx.doi.org). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this...

2014-01-14 12:26:37

PASADENA, Calif., Jan. 14, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing antibody-based products, today announced the appointment of inaugural members of its newly-formed scientific advisory board. The board will leverage its extensive experience in protein engineering to advise the company to help advance its proprietary monoclonal antibody (mAb) technology platform for the development of novel antibody-drug conjugates. "We are very proud to appoint...

2014-01-13 08:27:35

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome(TM) nanocage technology originally developed by Chimeros, Inc. The foundation of Chimerasome technology is a single protein that can be manipulated to form a spherical protein shell, which can encapsulate drugs and be coupled to antibodies externally, allowing very specific cellular targeting of the...

2013-12-16 04:21:30

LONDON and BOSTON, December 16, 2013 /PRNewswire/ -- Biased Agonist Antibodies Generated To G Protein-Coupled Receptor Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces the publication of a new scientific paper describing the use of StaR(R) proteins (thermostabilised G protein-coupled receptors, GPCRs) as antigens for antibody drug discovery. StaR proteins based on the beta1-adrenergic (beta1AR) receptor were...

2013-10-10 04:21:07

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, October 10, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013. The milestone is based on the generation of a stabilised (StaR(R)) form of the first GPCR target selected by MorphoSys, a key step...

2013-09-26 20:21:49

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates. Monoclonal antibodies are the most successful biologic therapeutics on the market. More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of...

2013-08-20 00:20:57

Merger with Immune Expected to Close this Week TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Aug. 20, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) (the "Company") and Immune Pharmaceuticals Ltd. announced today that, in accordance with EpiCept's recent stockholder approval and in preparation for the closing of the merger between the two companies, the 1-for-40 reverse stock split of EpiCept's common stock and the change in the Company's...

2013-08-07 16:28:24

Almost 92% of Votes Cast in Favor of Proposals TARRYTOWN, N.Y., Aug. 7, 2013 /PRNewswire/ -- EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced today that at its Special Meeting of Stockholders held on August 6, 2013, stockholders overwhelmingly approved the final conditions to the previously announced merger between Immune Pharmaceuticals Ltd. and EpiCept. Almost 92% of the votes were cast in favor of the proposals, representing more than 66% of...